Curacef duo, 50 mg/ml / 150 mg/ml, Suspension for Injection for Cattle

מדינה: אירלנד

שפה: אנגלית

מקור: HPRA (Health Products Regulatory Authority)

מרכיב פעיל:

Ceftiofur hydrochloride; Ketoprofen

זמין מ:

Virbac S.A.

קוד ATC:

QJ01DD

INN (שם בינלאומי):

Ceftiofur hydrochloride; Ketoprofen

כמות:

50,100 milligram(s)/millilitre

טופס פרצבטיות:

Suspension for injection

סוג מרשם:

POM: Prescription Only Medicine as defined in relevant national legislation

קבוצה תרפויטית:

Cattle

איזור תרפויטי:

Third-generation cephalosporins

סממני תרפויטית:

Antibacterial

מצב אישור:

Authorised

תאריך אישור:

2014-08-01

מאפייני מוצר

1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Curacef Duo 50 mg/ml + 150 mg/ml Suspension for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
Ceftiofur (as hydrochloride)
50.0
mg
Ketoprofen
150.0 mg
EXCIPIENTS:
QUALITATIVE COMPOSITION OF EXCIPIENTS AND
OTHER CONSTITUENTS
Sorbitan oleate
Hydrogenated soya lecithin
Cottonseed oil
Off - white to pinkish suspension for injection.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Cattle.
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
For the treatment of bovine respiratory disease (BRD) caused by
_Mannheimia haemolytica_
and
_Pasteurella multocida _
susceptible to ceftiofur and the reduction of associated
clinical signs of
inflammation or pyrexia.
3.3
CONTRAINDICATIONS
Do not use in cases of known resistance to other cephalosporins or
beta-lactam antibiotics.
Do not use in cases of hypersensitivity to ceftiofur and other

-lactam antibiotics.
Do not use in cases of hypersensitivity to ketoprofen.
Do
not
administer
other
non-steroidal
anti-inflammatory
drugs
(NSAIDs)
and
corticosteroids
concurrently or within 24 hours of each other.
Do not use in animals suffering from cardiac, hepatic or renal
disease, where there is the possibility of
gastro-intestinal ulceration or bleeding, where there is evidence of a
blood dyscrasia.
3.4
SPECIAL WARNINGS
None.
3.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for safe use in the target species:
The veterinary medicinal product selects for resistant strains such as
bacteria carrying extended
spectrum betalactamases (ESBL) and may constitute a risk to human
health if these strains disseminate
to humans e.g. via food. For this reason, the veterinary medicinal
product should be reserved for the
treatment of clinical conditions which have responded poorly, or are
expected to respond poorly
(refers to very acute cases when treatment must be initiated without
bacteriological diagnosis) to first
line treatment.
When inflammation or pyrexia have subsided, the veterinarian should
switch to